Literature DB >> 10807690

The Smith-Lemli-Opitz syndrome.

R I Kelley1, R C Hennekam.   

Abstract

The Smith-Lemli-Opitz syndrome (SLOS) is one of the archetypical multiple congenital malformation syndromes. The recent discovery of the biochemical cause of SLOS and the subsequent redefinition of SLOS as an inborn error of cholesterol metabolism have led to important new treatment possibilities for affected patients. Moreover, the recent recognition of the important role of cholesterol in vertebrate embryogenesis, especially with regard to the hedgehog embryonic signalling pathway and its effects on the expression of homeobox genes, has provided an explanation for the abnormal morphogenesis in the syndrome. The well known role of cholesterol in the formation of steroid hormones has also provided a possible explanation for the abnormal behavioural characteristics of SLOS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807690      PMCID: PMC1734573          DOI: 10.1136/jmg.37.5.321

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  161 in total

1.  Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS)

Authors:  E R Elias; M B Irons; A D Hurley; G S Tint; G Salen
Journal:  Am J Med Genet       Date:  1997-01-31

2.  Cataracts in the Smith-Lemli-Opitz syndrome.

Authors:  E Cotlier; P Rice
Journal:  Am J Ophthalmol       Date:  1971-11       Impact factor: 5.258

3.  Smith-Lemli-Optiz syndrome in a 23-year-old man.

Authors:  J G Deaton; L O Mendoza
Journal:  Arch Intern Med       Date:  1973-09

4.  Smith-Lemli-Opitz syndrome in an inbred family.

Authors:  S Nevo; A Benderly; J Levy; M B Katznelson
Journal:  Am J Dis Child       Date:  1972-09

5.  The Smith-Lemli-Opitz syndrome in a profoundly retarded epileptic boy.

Authors:  J E Chakanovskis; G R Sutherland
Journal:  J Ment Defic Res       Date:  1971-09

6.  Neurological involvement in the Smith-Lemli-Opitz syndrome: clinical and neuropathological findings.

Authors:  C A Garcia; P A McGarry; M Voirol; C Duncan
Journal:  Dev Med Child Neurol       Date:  1973-02       Impact factor: 5.449

7.  Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome.

Authors:  N A Nwokoro; J J Mulvihill
Journal:  Am J Med Genet       Date:  1997-01-31

8.  Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial.

Authors:  M Irons; E R Elias; D Abuelo; M J Bull; C L Greene; V P Johnson; L Keppen; C Schanen; G S Tint; G Salen
Journal:  Am J Med Genet       Date:  1997-01-31

9.  Pathogenesis of malformations in a rodent model for Smith-Lemli-Opitz syndrome.

Authors:  D B Dehart; L Lanoue; G S Tint; K K Sulik
Journal:  Am J Med Genet       Date:  1997-01-31

10.  Increased expression of low-density lipoprotein receptors in a Smith-Lemli-Opitz infant with elevated bilirubin levels.

Authors:  G C Ness; D Lopez; O Borrego; E Gilbert-Barness
Journal:  Am J Med Genet       Date:  1997-01-31
View more
  121 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

Review 2.  Malformation syndromes due to inborn errors of cholesterol synthesis.

Authors:  Forbes D Porter
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 3.  Infantile hypertrophic pyloric stenosis--genetics and syndromes.

Authors:  Babette Peeters; Marc A Benninga; Raoul C M Hennekam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-10       Impact factor: 46.802

4.  Metabolism of oxysterols derived from nonenzymatic oxidation of 7-dehydrocholesterol in cells.

Authors:  Libin Xu; Zeljka Korade; Dale A Rosado; Karoly Mirnics; Ned A Porter
Journal:  J Lipid Res       Date:  2013-02-04       Impact factor: 5.922

5.  Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome).

Authors:  Josep Marcos; Cedric H L Shackleton; Madhavee M Buddhikot; Forbes D Porter; Gordon L Watson
Journal:  Steroids       Date:  2007-07-13       Impact factor: 2.668

6.  Clinical utility gene card for: Smith-Lemli-Opitz Syndrome [SLOS].

Authors:  Martina Witsch-Baumgartner; Hilary Sawyer; Dorothea Haas
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

7.  Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets.

Authors:  J L Cross; J Iben; C L Simpson; A Thurm; S Swedo; E Tierney; J E Bailey-Wilson; L G Biesecker; F D Porter; C A Wassif
Journal:  Clin Genet       Date:  2014-06-06       Impact factor: 4.438

8.  Intracranial undifferentiated malign neuroglial tumor in Smith-Lemli-Opitz syndrome: A theory of a possible predisposing factor for primary brain tumors via a case report.

Authors:  Ayfer Aslan; Alp Ozgun Borcek; Selma Pamukcuoglu; M Kemali Baykaner
Journal:  Childs Nerv Syst       Date:  2016-08-15       Impact factor: 1.475

9.  Mutational analyses of UPIIIA, SHH, EFNB2 and HNF1beta in persistent cloaca and associated kidney malformations.

Authors:  Dagan Jenkins; Maria Bitner-Glindzicz; Louise Thomasson; Sue Malcolm; Stephanie A Warne; Sally A Feather; Sarah E Flanagan; Sian Ellard; Coralie Bingham; Lane Santos; Mark Henkemeyer; Andrew Zinn; Linda A Baker; Duncan T Wilcox; Adrian S Woolf
Journal:  J Pediatr Urol       Date:  2007-02       Impact factor: 1.830

10.  Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome.

Authors:  Elaine Tierney; Sandra K Conley; Halima Goodwin; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.